お知らせ :東京証券取引所JASDAQスタンダード市場への新規上場に関するお知らせ

株式会社グローバルインフォメーション
表紙
市場調査レポート
商品コード
247796

再発性悪性神経膠腫:パイプライン分析

Recurrent Malignant Glioma - Pipeline Review, H1 2020

出版日: | 発行: Global Markets Direct | ページ情報: 英文 55 Pages | 納期: 即納可能 即納可能とは

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=104.84円
再発性悪性神経膠腫:パイプライン分析
出版日: 2020年06月30日
発行: Global Markets Direct
ページ情報: 英文 55 Pages
納期: 即納可能 即納可能とは
担当者のコメント
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 図表
  • 目次
概要

再発性悪性神経膠腫は、治療後の腫瘍の再発として定義されます。治療には、化学療法や放射線療法などが含まれます。

当レポートでは、再発性悪性神経膠腫に対する治療薬の開発状況について調査分析し、パイプライン製品の概要、治験の段階別の製品の概要、主要企業プロファイル、薬剤のプロファイル、パイプライン製品の最新動向、最新ニュースとプレスリリースなどについて、体系的な情報を提供しています。

目次

イントロダクション

再発性悪性神経膠腫の概要

治療薬の開発

  • パイプライン製品:概要
  • パイプライン製品:比較分析

開発中の治療薬:企業別

調査中の治療薬:大学/研究機関別

パイプライン製品の概要

  • 治験段階の製品

開発中の製品:企業別

調査中の製品:大学/研究機関別

治療薬の開発に従事している企業

  • Amgen Inc.
  • AstraZeneca Plc
  • エーザイ
  • MediGene AG
  • Tiziana Life Sciences Plc
  • ZIOPHARM Oncology, Inc.

治療薬の評価

  • 単剤製品
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤のプロファイル

  • Ad-RTS-IL-12
  • Carboxyamidotriazole Orotate
  • Cell Therapy for Refractory Gliomas
  • Cell Therapy to Target IL-13 for Malignant Glioma
  • Dendritic Cell Therapy for Oncology
  • Dendritic Cell Therapy for Recurrent Malignant Glioma
  • disufenton sodium
  • DNX-2401
  • G-207
  • irofulven
  • milciclib
  • rilotumumab

パイプライン製品の最新動向

休止状態のプロジェクト

開発が中止された製品

製品開発のマイルストーン

  • 最新ニュースとプレスリリース

付録

図表

図表

List of Tables

List of Tables

  • Number of Products under Development for Recurrent Malignant Glioma, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products under Development by Universities/Institutes, H1 2020
  • Products under Development by Companies, H1 2020
  • Products under Development by Universities/Institutes, H1 2020
  • Number of Products by Stage and Target, H1 2020
  • Number of Products by Stage and Mechanism of Action, H1 2020
  • Number of Products by Stage and Route of Administration, H1 2020
  • Number of Products by Stage and Molecule Type, H1 2020
  • Recurrent Malignant Glioma - Pipeline by Anew Oncology Inc, H1 2020
  • Recurrent Malignant Glioma - Pipeline by Candel Therapeutics, H1 2020
  • Recurrent Malignant Glioma - Pipeline by GtreeBNT Co Ltd, H1 2020
  • Recurrent Malignant Glioma - Pipeline by Hebei Senlang Biotechnology Inc Ltd, H1 2020
  • Recurrent Malignant Glioma - Pipeline by Immunomic Therapeutics Inc, H1 2020
  • Recurrent Malignant Glioma - Pipeline by InSight Biopharmaceuticals Ltd, H1 2020
  • Recurrent Malignant Glioma - Pipeline by PharmAbcine Inc, H1 2020
  • Recurrent Malignant Glioma - Pipeline by Stella Pharmaceuticals Pvt Ltd, H1 2020
  • Recurrent Malignant Glioma - Dormant Projects, H1 2020
  • Recurrent Malignant Glioma - Dormant Projects, H1 2020 (Contd..1), H1 2020
  • Recurrent Malignant Glioma - Discontinued Products, H1 2020

List of Figures

List of Figures

  • Number of Products under Development for Recurrent Malignant Glioma, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products under Development by Universities/Institutes, H1 2020
  • Number of Products by Top 10 Targets, H1 2020
  • Number of Products by Stage and Top 10 Targets, H1 2020
  • Number of Products by Top 10 Mechanism of Actions, H1 2020
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
  • Number of Products by Top 10 Routes of Administration, H1 2020
  • Number of Products by Stage and Top 10 Routes of Administration, H1 2020
  • Number of Products by Top 10 Molecule Types, H1 2020
  • Number of Products by Stage and Top 10 Molecule Types, H1 2020
目次
Product Code: GMDHC12328IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Recurrent Malignant Glioma - Pipeline Review, H1 2020, provides an overview of the Recurrent Malignant Glioma (Oncology) pipeline landscape.

Recurrent malignant glioma is defined as recurrence of tumor after treatment. Symptoms include chest pain due to a tumor located in the chest area of the spinal cord, erectile dysfunction, lack of ability to feel changes in temperature, loss of muscle control, loss of bowel or bladder control, numbness or tingling, pain in the arm, neck, back, or leg caused by tumors in the neck area of the spinal cord and weakness in the limbs or upper body. Treatment includes chemotherapy and radiation therapy

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Recurrent Malignant Glioma - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Recurrent Malignant Glioma (Oncology)

The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Recurrent Malignant Glioma (Oncology) pipeline guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Unknown stages are 1, 4, 2 and 1 respectively. Similarly, the Universities portfolio in Phase II and Phase I stages comprises 4 and 1 molecules, respectively.

Recurrent Malignant Glioma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Recurrent Malignant Glioma (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Recurrent Malignant Glioma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Recurrent Malignant Glioma (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Recurrent Malignant Glioma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Recurrent Malignant Glioma (Oncology)

Reasons to Buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Recurrent Malignant Glioma (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Recurrent Malignant Glioma (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Recurrent Malignant Glioma - Overview
  • Recurrent Malignant Glioma - Therapeutics Development
  • Pipeline Overview
  • Pipeline by Companies
  • Pipeline by Universities/Institutes
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
  • Recurrent Malignant Glioma - Therapeutics Assessment
  • Assessment by Target
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Recurrent Malignant Glioma - Companies Involved in Therapeutics Development
  • Anew Oncology Inc
  • Candel Therapeutics
  • GtreeBNT Co Ltd
  • Hebei Senlang Biotechnology Inc Ltd
  • Immunomic Therapeutics Inc
  • InSight Biopharmaceuticals Ltd
  • PharmAbcine Inc
  • Stella Pharmaceuticals Pvt Ltd
  • Recurrent Malignant Glioma - Drug Profiles
  • bevacizumab biosimilar - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • bevacizumab biosimilar - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • bevacizumab biosimilar - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • borofalan - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Cellular Immunotherapy for Low-Grade Glioma and Recurrent Malignant Glioma - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • CIGB-128 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • disufenton sodium - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Gene Therapy to Target EphA2 for Recurrent Malignant Glioma - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Gene Therapy to Target IL-13 for Malignant Glioma - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • ITI-1000 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • rQNestin-34.5v.2 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • SENL-006 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Vaccine to Target URLC10, DEPDC1, FOXM1, KIF20A VEGFR1 and VEGFR2 for Malignant Glioma - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Recurrent Malignant Glioma - Dormant Projects
  • Recurrent Malignant Glioma - Discontinued Products
  • Recurrent Malignant Glioma - Product Development Milestones
  • Featured News & Press Releases
  • Apr 21, 2017: Japan's Ministry of Health, Labour and Welfare Announces SAKIGAKE Designation For Stella Pharma's Cancer Drug
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer
株式会社グローバルインフォメーション
© Copyright 1996-2021, Global Information, Inc. All rights reserved.